Gyroscope Therapeutics
Stevenage
About Gyroscope Therapeutics
Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON. Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $269.5M
- Funding stage: M&A
- Last round: Corporate Round (Nov 2021)
- Website: gyroscopetx.com
- Phone: +44 (0)1438 906770
Industries & Categories
Biotechnology, Genetics, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gyroscope-therapeutics-63803 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.